Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial

Autor: Stephanie Lowenhaupt, Debra Babcock, Bernard Ravina, Liana Baker, Pei Shieen Wong, Sheng Luo, Pauline LeBlanc, Barbara C. Tilley, Julie H. Carter, Robert A. Hauser, Nabila Dahodwala, Marina E. Emborg, David Simon, Rohit Dhall, John Y. Fang, Andrew Feigin, Richard M. Zweig, Jacci Bainbridge, John C. Morgan, Binit B. Shah, Karen Williams, Kathleen M. Shannon, Buff Farrow, Karl Kieburtz, Daniel D. Truong, Renee Wagner, Cindy Zadikoff, Tanya Simuni, Sofya Glazman, Carlos Singer, Mark F. Lew, Kelvin L. Chou, Rajesh Pahwa, Saloni Sharma, Cornelia Kamp, James T. Boyd, Jordan J. Elm, Maureen A. Leehey, John L. Goudreau, Burton L. Scott, Adriana Pérez, Franca Cambi, Ivan Bodis-Wollner, Anne-Marie Wills, Stephen L. Lee, Jay S. Schneider, G. Webster Ross, Richard B. Dewey

Publikováno v: The Lancet Neurology. 14:795-803

Summary Background A systematic assessment of potential disease-modifying compounds for Parkinson's disease concluded that pioglitazone could hold promise for the treatment of patients with this disease. We assessed the effect of pioglitazone on the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a49a30cdc60e8ef42e5f4cbc6242c5cb
https://doi.org/10.1016/s1474-4422(15)00144-1

A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease

Autor: Margaret Marie Cox, Stephanie Sendek, Margaret F. Turk, Julie H. Carter, Susan C. Fagan, Lorelei Derwent, Oksana Suchowersky, Jay S. Schneider, Linda Paul, Gwyn Vernon, Stephen Gollomp, Karl Kieburtz, Debbie Baker, I. Van Bodis-Wollner, Germaine McInnes, Marian A. Perez, G. Webster Ross, Katharine Pabst, Jorge L. Juncos, Chad W. Christine, Jessie Roth, Joseph M. Savitt, Peter A LeWitt, Hubert H. Fernandez, Matthew Brodsky, Mark F. Lew, Jay M. Gorell, Natividad R. Stover, Paulo Guimaraes, Andrew Feigin, Anita Blenke, Martha Nance, Elizabeth Hayes, Andrew Siderowf, W.R. Wayne Martin, Tammie Kelsey, Susan Bennett, Sharon McCarthy, Charles H. Adler, Beverly Olsen, Pauline LeBlanc, Richard B. Dewey, Rodger J. Elble, Richard S. Burns, Carlos Singer, Amy Parsons, John W. Taylor, Tracy Stewart, Maryan DeAngelis, Barbara C. Tilley, William J. Weiner, Brad A. Racette, Wendy R. Galpern, Michael J. Aminoff, Kapil D. Sethi, Jayaraman Rao, Robert A. Hauser, Debbie Fraser, Connie Kawai, David Coffey, Kelly E. Lyons, Kristine Wernette, Becky Dunlop, Holly Delgado, Marlene Lind, Rajesh Pahwa, Chris Weaver, Ray L. Watts, Patricia Deppen, Ryan J. Uitti, Marwan N. Sabbagh, Lynn Marlor, Joann Belden, Burton L. Scott, Theresa McClain, Roger L. Albin, John Y. Fang, Zoran Obradov, Yuko Y. Palesch, Maureen Cook, Pamela Andrews, Jeana Jaglin, Joanne Wojcieszek, Mary Louise Musante Weeks, Susan Peterson, James H. Bower, Maureen A. Leehey, Joanne Field, Lisa M. Shulman, Caroline M. Tanner, Jacob I. Sage, Jordan J. Elm, Joseph Jankovic, Patrick D. Mauldin, Aileen Shinaman, Peng Huang, G. Frederick Wooten, Alicia Brocht, Gordon H. Brown, Peggy Roberge, Dorothy Shearon, Buff Dill, Margaret F. Keller, Charlene Young, Christine Hunter, Janis M. Miyasaki, Susan Torgrimson, Cornelia Kamp, Brigid Hayward, Christopher G. Goetz, Emily Kosa, Marilyn Flewellen, David Simon, Rebecca McMurray, Sue Reichwein, Jacci Bainbridge, Robert W. Hamill, Stephanie Terashita, Kathleen M. Shannon, Frederick Wooten, Danna Jennings, Shana Krstevska, Bernard Ravina

Publikováno v: Neurology. 68:20-28

Objective: To determine if future studies of coenzyme Q10 and GPI-1485 in Parkinson disease (PD) may be warranted. Methods: We conducted a randomized, double-blind, calibrated futility clinical trial of coenzyme Q10 and GPI-1485 in early untreated PD

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36f17ff7b2eee66f71cf67f7561841fe
https://doi.org/10.1212/01.wnl.0000250355.28474.8e